Medicus Pharma Seeks SkinJect Designation
Analysis based on 7 articles · First reported Jun 15, 2026 · Last updated Jun 15, 2026
The submission of Rare Pediatric Disease Designation for Skinject by Medicus Pharma could significantly accelerate the drug's review process by the United States — Food and Drug Administration, potentially leading to earlier market access and a period of market exclusivity. This positive regulatory step is likely to be viewed favorably by investors, potentially boosting Medicus Pharma's stock price due to the increased likelihood of a successful product launch in a niche market.
Medicus Pharma Ltd. submitted a Rare Pediatric Disease Designation (RPDD) request to the United States — Food and Drug Administration for Skinject, an investigational microneedle patch for treating basal cell carcinoma in patients with Gorlin Syndrome. This follows a previous application for Orphan Drug Designation and a proposed registrational study design, both still under United States — Food and Drug Administration review. Skinject, designed to deliver doxorubicin directly to lesions, showed positive results in a Phase 2 study, achieving 64% clinical clearance and 55% complete response rates. Gorlin Syndrome is a rare genetic disorder causing numerous basal cell carcinomas, often starting in childhood. The RPDD, if granted, could lead to a Priority Review Voucher, potentially reducing United States — Food and Drug Administration review time for a future New Drug Application and offering seven years of U.S. market exclusivity if approved. Raza Bokhari, Medicus Pharma's Executive Chairman and CEO, highlighted Skinject's potential as a non-surgical treatment option for these patients.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard